A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo scoreCTS-CLINICAL AND TRANSLATIONAL SCIENCEIF2.82023-09-221OAAI
First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteersCTS-CLINICAL AND TRANSLATIONAL SCIENCEIF2.82023-07-2322OA
Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitisCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32022-07-293OA
Exposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitisCPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYIF32022-07-182OA
Safety, Tolerability, and Pharmacokinetics of High-Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy VolunteersCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52021-08-2712PREAI
Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's diseaseALZHEIMERS RESEARCH & THERAPYIF7.62020-01-2240OAAI
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumorsANNALS OF ONCOLOGYIF65.42018-05-0157OAAI
Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase InhibitorCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52018-03-2358PREAI